CKPT(Delisted)
CheckpointยทNASDAQ
--
--(--)
CKPT Profile
Checkpoint Therapeutics, Inc.
A clinical-stage immunotherapy and targeted oncology company that developing treatments for solid tumor cancers
95 Sawyer Road, Suite 110, Waltham, Massachusetts 02453
--
Checkpoint Therapeutics, Inc., was incorporated in Delaware on November 10, 2014. The Company is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of new therapies for patients with solid tumor cancer. The Company is evaluating its lead antibody candidate, cosibelimab, an anti-programmed death ligand 1 (" PD-L1 ") antibody licensed by the Dana-Farber Cancer Institute (" Dana-Farber "), in a global, open-label, multi-cohort Phase 1 clinical trial for the checkpoint treatment of newly diagnosed patients with specific relapsed or metastatic cancers, This includes an ongoing cohort of locally advanced and metastatic skin squamous cell carcinoma (" CSCC ") designed to support one or more marketing approval applications.
